Fluad trivalent influenza vaccine risk to patients with latex allergy

26 Apr 2018

The Therapeutic Goods Administration (TGA) has investigated a report and confirmed the presence of natural rubber latex in the sheath covering the needle of the trivalent influenza vaccine, Fluad, which is available for people aged 65 years and over through the National Immunisation Program (NIP).

While reactions to latex are rare, anyone who has a severe allergy to latex should not receive Fluad. Patients aged 65 years and over can still be safely vaccinated with the alternative trivalent influenza vaccine, Fluzone High-Dose, available through the NIP.

Please note there are no safety concerns regarding the Fluad vaccine itself.

The sponsor of Fluad, Seqirus, commits to update the Product Information and Consumer Medicines Information for this vaccine accordingly. Action for vaccination providers:

  • If you are vaccinating patients with Fluad, please be aware of this issue and advise patients accordingly. Reassure patients that reactions to latex are rare.
  • Before administering Fluad, confirm with patients that they are not allergic to latex.
  • Anyone who has a severe allergy to latex should not receive Fluad. Patients aged 65 years and over can still be safely vaccinated with the alternative trivalent influenza vaccine, Fluzone High‑Dose (sponsored by Sanofi Pasteur), available through the NIP.
  • As with all vaccinations, be prepared to treat immediate allergic reactions, including potential anaphylaxis.
  • If you have any questions or concerns about this issue, contact Seqirus on 1800 642 865.

For further information head to the Department of TGA’s page on fluad trivalent influenza vaccine: Safety advisory – risk to patients with latex allergy.